Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 12, 2013, Pages 1394-1398

  Farkas, Klaudia ^a   Lakatos, Péter László ^b   Nagy, Ferenc ^a   Szepes, Zoltán ^a   Miheller, Pál ^b   Papp, Mária ^c   Palatka, Károly ^c   Bálint, Anita ^a   Bor, Renáta ^a   Wittmann, Tibor ^a   Molnár, Tamás ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

discontinuation; Infliximab therapy; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE;

ADULT; AGED; APPENDECTOMY; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; COLONOSCOPY; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; RETREATMENT; SMOKING; STEROID THERAPY; ULCERATIVE COLITIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892145631     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.845906     Document Type: Article

References (6)

1. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict responsé Am J Gastroenterol 2011;106:199-212
2. Molnar T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013;37:225-33
3. Steenholdt C, Molazahi A, Ainrworth MA, et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: An observational Danish single center study. Scand J Gastroenterol 2012;47: 518-27
4. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70
5. Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012;18:174-9
6. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29